3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
98
pembrolizumab
87
Gemcitabine
81
Carboplatin
63
fludarabine
62
Nivolumab
57
Cisplatin
54
Paclitaxel
51
Radiotherapy
50
Docetaxel
50
Rituximab
46
Dexamethasone
42
Lenalidomide
41
Ipilimumab
38
Azacitidine
35
Etoposide
34
Cytarabine
34
Temozolomide
32
Bevacizumab
32
Radiation
29
venetoclax
28
Bortezomib
27
Magnetic Resonance Spectroscopy
26
Irinotecan
26
atezolizumab
25
Pemetrexed
25
Oxaliplatin
24
Capecitabine
24
fludarabine phosphate
23
Filgrastim
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Terminated
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled